Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

NCT00924352 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Dasatinib
DRUG: Ixabepilone

Sponsor

Accelerated Community Oncology Research Network

Collaborators

[object Object]